Table 1.
Clinical characteristics of the study population before treatment
| Characteristics | n = 23 |
|---|---|
| Age (years) | 42.7 ± 10.0 |
| Height (cm) | 156.1 ± 31.2 |
| Weight (kg) | 66.8 ± 11.1 |
| Gender (male/female) | 8/15 |
| Wheeze score | 1.30 ± 1.06 |
| Cough score | 1.43 ± 0.99 |
| Daily SABA use* | 1.74 ± 3.33 |
| Asthma score | 5.13 ± 4.50 |
| FEV1 (% predicted) | 79.01 ± 17.89 |
| FEV1/FVC (%) | 65.86 ± 10.28 |
| PEF (% predicted) | 85.39 ± 24.14 |
| FEF50 (% predicted) | 41.43 ± 21.17 |
| FEF75 (% predicted) | 37.23 ± 21.61 |
| MMEF (% predicted) | 42.69 ± 22.46 |
Values are means ± SD, except for gender, which are patient numbers. *Times of daily use of 100 μg salbutamol. FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; FEF50: Forced expiratory flow at 50% of FVC; FEF75: Forced expiratory flow at 75% of FVC; MMEF: Maximum mid-expiratory flow rate; PEF: Peak expiratory flow; SABA: Short-acting β2-agonist; SD: Standard deviation.